A5027081875- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- Pneumocystis jirovecii pneumonia detection and treatment
- SARS-CoV-2 and COVID-19 Research
- Antifungal resistance and susceptibility
- HIV-related health complications and treatments
- Nail Diseases and Treatments
- Fungal Infections and Studies
- Hepatitis C virus research
- Biochemical and Molecular Research
- COVID-19 Clinical Research Studies
- Cytomegalovirus and herpesvirus research
- SARS-CoV-2 detection and testing
- Mycobacterium research and diagnosis
- Biosensors and Analytical Detection
- Toxoplasma gondii Research Studies
- Nanoplatforms for cancer theranostics
- Infectious Diseases and Mycology
- Herpesvirus Infections and Treatments
- Immune Cell Function and Interaction
- Genomics and Rare Diseases
- Skin Diseases and Diabetes
- Dermatological and Skeletal Disorders
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
Hoag Orthopedic Institute
2025
Université de Montpellier
1998-2024
Centre Hospitalier Universitaire de Montpellier
2004-2023
Hospital General Universitario de Albacete
2023
Institut de Virologie
1996-2021
Inserm
2021
Institut Pasteur
2021
Hôpital Saint Eloi
2002-2019
Hôpital Lapeyronie
2019
Complejo Hospitalario de Navarra
2018
ABSTRACT Raltegravir (MK-0518) is a potent inhibitor of human immunodeficiency virus (HIV) integrase and clinically effective against viruses resistant to other classes antiretroviral agents. However, it can select mutations in the HIV gene. Nine heavily pretreated patients who received salvage therapy including raltegravir subsequently developed virological failure under were studied. For each patient, sequences integrase-coding region determined compared that at beginning treatment. Four...
Significance A detailed characterization of viral load kinetics and its association with disease evolution is key to understand the virus pathogenesis, identify high-risk patients, design better treatment strategies. We here analyze mortality virological information collected in 655 hospitalized including 284 longitudinal measurements, we build a mathematical model dynamics survival. predict that peak occurs 1 d before symptom onset, on average, decline after slower older patients. Viral...
The development and validation of dried sample spots as a method specimen collection are urgently needed in developing countries for monitoring human immunodeficiency virus (HIV) infection. Our aim was to test some crucial steps the use spots, i.e., viral recovery storage over time. Moreover, we investigated whether plasma blood (DPS DBS, respectively) give comparable load (VL) results. Four manual RNA extraction methods from commercial HIV type 1 (HIV-1) VL assays--a QIAamp minikit...
The SARS-CoV-2 genome occupies a unique place in infection biology - it is the most highly sequenced on earth (making up over 20% of public sequencing datasets) with fine scale information sampling date and geography, has been subject to unprecedented intense analysis. As result, these phylogenetic data are an incredibly valuable resource for science health. However, vast majority was by tiling amplicons across full genome, amplicon schemes that changed pandemic as mutations viral interacted...
Assessment of genotypic changes in the reverse transcriptase gene HIV-1 occurring antiretroviral naive patients treated by stavudine plus didanosine combination therapy.Sequence analysis (codons 1-230) was performed after amplification from plasma samples collected at baseline and end treatment 39 previously treatment-naive for 24-48 weeks.At baseline, mutations associated with zidovudine resistance were detected two patients: Asp67Asn/Lys219Gln Leu210Trp. Among subjects, 18 (46%) developed...
Reverse transcriptase-coupled polymerase chain reaction (Amplicor HIV-1 Monitor), the branched DNA (bDNA) method (Quantiplex RNA) and nucleic acid sequence-based assay (NASBA RNA QT) were comparatively evaluated for quantitation of human immunodeficiency virus type 1 (HIV-1) in plasma. Among 60 plasma specimens from infected patients, was detected 56 by Amplicor (sensitivity, 93.3%), 41 bDNA 68.3%), NASBA 100%). not any these methods 34/34 HIV-1-seronegative blood donors (specificity, The...
Genotypic algorithms for prediction of HIV-1 coreceptor usage need to be evaluated in a clinical setting. We aimed at studying (i) the correlation genotypic use comparison with phenotypic assay and (ii) relationship between baseline virological response (VR) therapy including maraviroc (MVC). Antiretroviral-experienced patients were included MVC Expanded Access Program if they had an R5 screening result Trofile (Monogram Biosciences). V3 loop sequences determined screening, was predicted...
Management of relapsing or refractory immune reconstitution inflammatory syndromes (IRISs) despite corticosteroid therapy is yet to be defined. We describe three HIV-infected patients with corticosteroid-dependent and life-threatening paradoxical syndrome for whom thalidomide treatment induced rapid clinical remission permitted complete withdrawal without relapse.
Abstract Objectives The objectives of this study were to determine the prevalence and patterns resistance integrase strand transfer inhibitors (INSTIs) in patients experiencing virological failure on raltegravir-based ART impact susceptibility INSTIs (raltegravir, elvitegravir dolutegravir). Patients methods Data collected from 502 treatment-experienced failing a raltegravir-containing regimen multicentre study. Reverse transcriptase, protease sequenced at for each patient. INSTI...
The implementation of rapid diagnostic tests (RDTs) may enhance the efficiency severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing, as RDTs are widely accessible and easy to use. aim this study was evaluate performance a diagnosis strategy based on combination antigen immunoglobulin M (IgM) or G (IgG) serological RDTs. Plasma nasopharyngeal samples were collected between 14 March 11 April 2020 at hospital admission from 45 patients with reverse transcription polymerase chain...
To estimate the prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-1-infected patients France. Resistance were sought samples from 530 newly diagnosed October 2006 to March 2007. Protease reverse transcriptase identified 2007 Stanford Surveillance list. Reverse protease determined 466 with duration seropositivity <5 years. 42% infected strains (CRF02 18.3%). The overall viruses or was 10.6% (95% confidence interval...
The DOLULAM study assessed the efficacy of dolutegravir + lamivudine dual therapy to maintain virological suppression in heavily treatment-experienced HIV-1-infected adults. No failure occurred during first year therapy.A substudy was conducted assess prevalence M184I/V mutations at initiation using historical DNA/RNA genotypes and baseline DNA genotype obtained by next-generation sequencing (NGS).HIV-1 RT sequences were from and/or RNA Sanger technology. HIV-1 integrase NGS performed...
To assess the phenotypic susceptibility of E157Q polymorphism in HIV-1 integrase (IN) and virological outcome patients infected with E157Q-mutated virus initiating an IN inhibitor (INI)-based regimen.This was a multicentre study assessing sequences from INI-naive among 17 French HIV clinical centres. site-directed mutants pNL4.3 pCRF02_AG contexts were assessed recombinant assay.Prevalence 2.7% 8528 its distribution 1.7%, 5.6% 2.2% B, CRF02_AG various non-B subtypes, respectively....
Resistance-mutation patterns in the reverse transcriptase (RT) and protease genes of HIV-1 were analyzed 22 patients who had been extensively pretreated failed to respond highly active antiretroviral therapy (HAART). The number mutations ranged from 8 19 (median, 13): 4 12 6) RT gene, 7) gene. In most frequent resistance found at codons 215 (100%), 41 (95%), 67 (91%), 210 (77%). Multidrug-resistant mutation including Q151M insertion codon 69, which confer cross-resistance different...
To identify mutations associated with the virological response (VR) to a tipranavir-ritonavir (TPV/r)-based regimen, 143 patients previously treated protease inhibitor (PI) were studied. VR was defined by decrease of at least 1 log(10) in, or undetectable, human immunodeficiency virus (HIV) RNA month 3. The effect each mutation in protease, considering all variants residue as single variable, on TPV/r investigated. Mutations six residues lower (E35D/G/K/N, M36I/L/V, Q58E, Q61D/E/G/H/N/R,...
Background: Surveillance of HIV-1 resistance in treated patients with a detectable viral load (VL) is important to monitor, order assess the risk spread resistant viruses and determine proportion who need new antiretroviral drugs minimal cross-resistance. Methods: The protease reverse transcriptase (RT) integrase genes were sequenced plasma samples from 782 consecutive on failing regimens, seen 37 specialized centres 2014. genotyping results interpreted using ANRS v24 algorithm. Prevalence...
To assess the genotypic determinants of virological response to tenofovir disoproxil fumarate (TDF) in a multicentre cohort antiretroviral (ARV)-experienced patients receiving TDF as part salvage therapy.HIV-1 genotype was assessed at baseline subgroup 161 French expanded access program stable TDF-including regimen for 3 months or more. Reverse transcriptase mutations associated with viral load decrease month P-value <0.15 were retained construction mutation score. The score then validated...
Objective: To compare the prevalence of mutations associated with resistance to antiretroviral drugs and their interpretation in patients infected non-B HIV-1 variants versus HIV-1subtype B–infected similar treatment regimens. Methods: The reverse transcriptase (RT) protease genes were sequenced, subtypes determined by phylogenetic analysis. Each sequence belonging a variant was matched subtype B. Patterns interpreted terms drug using HIV db algorithm. Results: RT M41L, L210W, and, lesser...
Minority resistant variants of human immunodeficiency virus type 1 (HIV-1) could influence the virological response to treatment based on nonnucleoside reverse transcriptase inhibitors (NNRTIs). Data minority rilpivirine-resistant are scarce. This study used next-generation sequencing (NGS) identify patients harboring nucleos(t)ide and NNRTIs assess their (VR).All subjects, 541 HIV-1-infected started a first-line regimen containing rilpivirine. VR was defined as HIV-1 RNA load <50 copies/mL...
Abstract Objectives As many disparities in the clinical use of HIV DNA sequencing are observed, a DELPHI-type consensus was initiated France to homogenize use, techniques and interpretation results. Methods Based on literature review experience, steering committee (SC) eight virologists one infectious disease specialist formulated statements. Statements were submitted an independent anonymous electronic vote clinicians France, between October 2022 December 2022. Results The SC developed 20...
To describe integrase strand transfer inhibitor (INSTI) resistance profiles and factors associated with in antiretroviral-naive -experienced patients failing an INSTI-based regimen clinical practice.Data were collected from INSTI-containing a multicentre French study between 2014 2017. Failure was defined as two consecutive plasma viral loads (VL) >50 copies/mL. Reverse transcriptase, protease coding regions sequenced at baseline failure. INSTI resistance-associated mutations (RAMs) included...
Limited information exists on nursing home (NH) residents regarding BNT162b2 vaccine efficacy in preventing SARS-CoV-2 and severe COVID-19, its association with post-vaccine humoral response.396 from seven NHs suffering a B.1.1.7 (VOC-α) outbreak at least 14 days after campaign were repeatedly tested using real-time reverse-transcriptase polymerase chain reaction nasopharyngeal swab test (RT-qPCR). receptor-binding domain (RBD) of the S1 subunit (RBD-IgG) was measured all residents....
ABSTRACT We compared the QUANTIPLEX HIV-1 RNA 2.0 assay with AMPLICOR MONITOR 1.0 for quantitation of human immunodeficiency virus type 1 (HIV-1) in plasma Stadi trail, which evaluated a stavudine plus didanosine combination therapy 52 patients. baseline values measured were significantly higher than those 2.0, and decreases levels from also found to be when assay. The frequency below lower limit was 1.0. Reanalysis these results by an ultrasensitive procedure or modified version test that...